GLP-1 peptides have become some of the most talked-about drugs in the world because of their effects on weight loss. Now, scientists are asking a much bigger question: could these same compounds also influence the biological processes linked to Alzheimer’s disease? A new review examines the evidence so far.What Do GLP-1 Drugs Do to Alzheimer’s Disease Biomarkers? Image by MagnificNote: This article is intended for general information and educational purposes. It summarizes scientific research in accessible language for a broad audience and is not an official scientific press release.Investigating the mechanisms of nervous tissue degeneration and finding ways to counteract them remain critically important directions in global cognitive science, given the rising global incidence of Alzheimer’s disease (AD). On April 20, 2026, the journal Molecular and Cellular Neuroscience published a systematic review titled “The effects of GLP-1 receptor agonists on Alzheimer’s pathophysiology: A systematic review”.The paper was authored by Eve Corcoran, Michael Kettlety, Urwa Mogul, Jennifer Ndiforngwah Azah, and Simon C. Cork from the School of Medicine at Anglia Ruskin University (Chelmsford, UK). The purpose of this study was to systematically evaluate and consolidate available preclinical and clinical data regarding how glucagon-like peptide-1 receptor (GLP-1R) agonists affect the primary biological biomarkers associated with Alzheimer’s pathology.What the Researchers InvestigatedAlzheimer’s disease pathophysiology is fundamentally characterized by two microscopic hallmarks: the accumulation of insoluble beta-amyloid (Aβ) plaques and the formation of neurofibrillary tangles from hyperphosphorylated tau proteins. The buildup of Aβ triggers localized neuroinflammation, while dysfunctional tau protein impairs cellular transport, ultimately resulting in synaptic loss and neuronal cell death, particularly within the hippocampus.The authors investigated whether GLP-1R agonists, which are conventionally utilized to treat type 2 diabetes and obesity, may possess neuroprotective properties. The review focused on four specific peptide agents: liraglutide, semaglutide, exenatide, and dulaglutide. The investigators sought to clarify whether these compounds could directly or indirectly reduce amyloid plaque burden and mitigate the hyperphosphorylation of tau across various experimental settings.How the Review Was ConductedFollowing PRISMA guidelines, the authors conducted a comprehensive literature search across major electronic databases, including PubMed, Embase, and the Cochrane Library. The search relied on combinations of specific terms such as “GLP-1 mimetic,” “GLP-1 agonist,” “Alzheimer’s pathophysiology,” “Beta amyloid plaques,” and “Tau hyperphosphorylation”.The selection process was guided by precise eligibility rules:• Inclusion Criteria: Peer-reviewed preclinical (cell lines or animal models) and clinical (human) randomized or non-randomised studies published between January 1, 2015, and April 1, 2025. Studies had to measure the effects of liraglutide, dulaglutide, semaglutide, or exenatide on Aβ and/or tau pathology and include a defined control or comparator group.• Exclusion Criteria: Studies evaluating any GLP-1 mimetics outside of the specified list; research focused on non-AD neurological conditions (such as stroke or Parkinson’s disease); observational designs, non-peer-reviewed abstracts, or papers reporting cognitive outcomes without any direct measurements of Aβ or tau status.Out of 1,749 initially identified records, 264 duplicates were removed. Following a multi-stage screening of titles, abstracts, and full texts, the authors identified 32 eligible studies: 30 preclinical models and 2 human clinical trials. Due to the high heterogeneity of outcome measures, a statistical meta-analysis was not performed; instead, data extraction was presented through a standardized qualitative review.What This Review Adds to Existing ResearchCompared to previous research, this paper emphasizes the direct physical burden of AD biomarkers rather than relying solely on symptomatic or behavioral data. The authors highlight that by focusing on quantitative changes in amyloid and tau, their review isolates the core structural pathology. This approach bypasses a common limitation of many preclinical animal models, which artificially elevate Aβ and tau but frequently lack the widespread, age-related neuronal loss seen in human patients.Furthermore, this review is among the first to directly contrast the generally positive findings reported in laboratory settings with the limited and mixed evidence currently available from controlled human clinical trials.Key FindingsThe systematic analysis of thirty preclinical papers revealed a highly consistent trend of biomarker reduction in laboratory environments, although outcomes varied depending on the peptide analyzed.LiraglutideInvestigated across 17 different experimental paradigms, liraglutide yielded the most substantial body of evidence. In cell preparations and rodent models, it consistently reduced both Aβ load and tau pathology. In a non-human primate model, treatment with liraglutide prior to toxic amyloid exposure resulted in a significant reduction in hyperphosphorylated tau and prevented subsequent synaptic loss.Analyses showed that while hyperphosphorylated tau was reduced, total tau concentrations often remained unchanged, suggesting that the peptide primarily influenced phosphorylation status rather than overall protein expression. Region-specific variations were also noted; one mouse model showed decreased Aβ in the cortex but no change in the hippocampus.DulaglutideAlthough only two studies met the review criteria, the included mouse studies reported reductions in tau phosphorylation and Aβ accumulation, along with improvements in learning and memory measures.SemaglutideEvaluated in four mouse studies, semaglutide showed largely positive outcomes, with three papers reporting reductions in Aβ or tau-related pathology. However, some findings introduced additional complexity. Germano and colleagues reported no effect on overall Aβ levels in male or female 5xFAD mice or male APP/PS1 mice, while observing a reduction in plaque intensity specifically within the hippocampus of female treated mice.Exenatide (Exendin-4)Evidence regarding exenatide was more mixed compared to liraglutide. Several studies demonstrated decreased accumulation of Aβ1-42 deposits in the hippocampus and prefrontal cortex. One cellular study found reduced tau hyperphosphorylation only when Exendin-4 was administered in the presence of insulin.TirzepatideTirzepatide was evaluated in a single included study. Unlike several other GLP-1 receptor agonists reviewed in the paper, it did not show reductions in amyloid plaque measures within the hippocampus of 5xFAD mice. The study also reported an increase in plaque area within the cerebral cortex of male mice.Human Clinical FindingsData from the two analyzed human trials revealed a noticeable divergence from the preclinical findings.A 26-week randomized, double-blind, placebo-controlled trial of liraglutide in patients with established Alzheimer’s disease demonstrated no reduction in total amyloid plaque burden or cognitive scores, although the study reported preservation of brain glucose consumption.An 18-month phase II clinical trial of exenatide in individuals with mild cognitive impairment or mild dementia found no significant changes in Aβ or tau within cerebrospinal fluid or general plasma samples. However, according to the authors, a significant decrease in Aβ42 was detected within plasma neuronal extracellular vesicles.Authors’ ConclusionsAccording to the authors, the available evidence suggests that GLP-1R agonists may influence Aβ and tau pathology through four primary biological pathways:1. Suppression of BACE1. Liraglutide appears to suppress the expression of BACE1, the enzyme responsible for cleaving amyloid precursor protein into harmful amyloidogenic fragments.2. Amelioration of Insulin Resistance. By activating the PI3K/AKT signaling pathway, these compounds increase the phosphorylation and inhibition of GSK3β. In insulin-resistant states, uninhibited GSK3β contributes to tau hyperphosphorylation. Improved insulin signaling may therefore influence this process.3. Reduction of Systemic Inflammation. The peptides interact with receptors on immune cells and may reduce inflammatory cytokines such as TNF-α, IL-1β, and IL-6, which have been implicated in neuroinflammatory processes associated with Alzheimer’s disease. The authors note that post hoc analyses of the EXSCEL trial reported reductions in circulating inflammatory biomarkers.4. Cardiovascular Effects. According to the authors, the established cardiovascular effects of these drugs may represent an indirect mechanism relevant to dementia-related pathology and risk.The authors also point out major limitations in the current literature. Much of the evidence demonstrating tau reduction originates from metabolically impaired or diabetic models. As a result, it remains unclear whether these peptides exert direct effects on tau phosphorylation independent of improvements in systemic metabolic function. In addition, human clinical evidence remains limited.Understanding the Broader ContextThese findings contribute to a growing scientific discussion regarding the relationship between metabolic health and neurodegenerative disease. The authors note that large retrospective studies, including those by Nørgaard et al. and Tang et al., reported a lower incidence of future dementia diagnoses among people with type 2 diabetes who received GLP-1 receptor agonists compared with some alternative glucose-lowering medications.However, the review also highlights that current clinical studies involving individuals with established Alzheimer’s disease have not demonstrated clear effects on cognitive decline. According to the authors, additional research is needed to clarify how the biomarker findings observed in experimental models relate to clinical outcomes in humans.ConclusionThe reviewed results add to ongoing research exploring how metabolic regulation interacts with neurodegenerative processes. The systematic review reports consistent preclinical evidence that GLP-1R agonists reduce structural pathobiomarkers in laboratory models. Most experimental studies reported reductions in amyloid plaques and/or tau pathology, with particularly consistent findings for liraglutide and largely positive findings for semaglutide and dulaglutide. Evidence for exenatide was more mixed, while tirzepatide did not demonstrate a clear positive signal in the single study included in the review. However, their ability to alter cognitive outcomes in humans remains uncertain.What remains unknown is the precise degree of central nervous system exposure achieved by these compounds in humans, as well as whether biomarker changes translate into measurable clinical outcomes. Future large-scale studies will be needed to determine whether the biomarker changes observed in experimental settings translate into measurable clinical outcomes in humans.The information in this article is provided for informational purposes only and is not medical advice. For medical advice, please consult your doctor.ReferenceCorcoran, E., Kettlety, M., Mogul, U., Ndiforngwah Azah, J., & Cork, S. C. (2026). The effects of GLP-1 receptor agonists on Alzheimer’s pathophysiology: A systematic review. Molecular and Cellular Neuroscience, 104091. https://doi.org/10.1016/j.mcn.2026.104091The post Can Peptides Slow the Progress of Alzheimer’s Disease? A New Scientific Review appeared first on CogniFit Blog: Brain Health News.